NASDAQ:CBMG Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis → This TSLA short trade is on a nine win hot streak (From WealthPress) (Ad) Free CBMG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$17.67▼$19.7552-Week Range N/AVolume8,375 shsAverage Volume129,776 shsMarket Capitalization$384.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cellular Biomedicine Group alerts: Email Address Ad Wealthpin ProDo This Before July 30 2024 To Claim Trump’s Gift In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About Cellular Biomedicine Group Stock (NASDAQ:CBMG)Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Read More Ad Wealthpin ProAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. CBMG Stock News HeadlinesMay 29 at 6:14 PM | msn.comT-Mobile Swallows Up Most Of US Cellular For $4.4 BillionMay 29 at 6:14 PM | bizjournals.comUS Cellular selling most of its assets to T-Mobile for $4.4 billionMay 29 at 8:11 AM | finance.yahoo.comT Mobile to acquire US Cellular for $4.4bnMay 29 at 8:11 AM | finance.yahoo.comUnited States Cellular Corporation's (NYSE:USM) Intrinsic Value Is Potentially 88% Above Its Share PriceMay 29 at 1:36 AM | msn.comT-Mobile is set to buy US Cellular for $4.4billion - here is what it can mean for your serviceMay 28 at 3:23 PM | msn.comWhy T-Mobile Buying US Cellular Could Be A Disaster For Budget Cellphone PlansMay 28 at 3:23 PM | msn.comT-Mobile to buy almost all of US Cellular in deal worth $4.4 billionMay 28 at 3:23 PM | msn.comT-Mobile to buy US Cellular's wireless ops, plus slice of spectrum for $4.4BMay 28 at 3:23 PM | msn.comT-Mobile acquires US Cellular assets for $4.4 billion as carrier aims to boost rural connectivityMay 28 at 3:23 PM | msn.comT-Mobile signs a $4.4 billion deal to buy most of US CellularMay 28 at 10:23 AM | msn.comT-Mobile to acquire almost all of US Cellular in $4.4 billion deal including debtMay 28 at 10:23 AM | 9to5mac.comT-Mobile buying US Cellular; says rural coverage will improveMay 28 at 10:23 AM | msn.comT-Mobile to buy most of US Cellular in $4.4 billion dealMay 24, 2024 | finanznachrichten.deMillicom International Cellular S.A.: Millicom (Tigo) comments on shareholder communicationMay 23, 2024 | benzinga.comHARRY HARCZAK JR's Recent Buy: Acquires $121K In United States Cellular StockMay 23, 2024 | benzinga.comDeirdre Drake's Recent Buy: Acquires $121K In United States Cellular StockMay 22, 2024 | msn.comScore the Apple Watch Series 9 GPS/Cellular for $389 Today Only!May 16, 2024 | msn.comApple Watch Series 9 drops to $329 ($429 for GPS + Cellular)May 16, 2024 | markets.businessinsider.comIdea Cellular earnings: here's what to expectMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical TrialsMay 9, 2024 | msn.comMillicom International Cellular S.A. (NASDAQ:TIGO) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comIntra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkApril 30, 2024 | seekingalpha.comIntra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A BuyApril 25, 2024 | finance.yahoo.comThe 500 Largest Cellular IoT Projects Worldwide - 7th EditionApril 22, 2024 | markets.businessinsider.comBuy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder MarketSee More Headlines Receive CBMG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellular Biomedicine Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2020Today5/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBMG CUSIPN/A CIK1378624 Webwww.cellbiomedgroup.com Phone347-905-5663FaxN/AEmployees217Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-144.80% Return on Assets-61.68% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$340,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / BookN/AMiscellaneous Outstanding Shares19,478,000Free FloatN/AMarket Cap$384.69 million OptionableOptionable Beta1.35 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Bizuo Liu (Age 56)CEO, CFO & Exec. Director Comp: $541.33kDr. Yihong Yao (Age 53)Chief Scientific Officer Comp: $364.98kMr. Andrew K. Chan (Age 63)Chief Legal Officer (Gen. Counsel), Sr. VP of Corp. Devel. & Sec. Comp: $475.08kMr. Derrick C. LiHead of Strategy & Investor RelationsMs. Sarah KellyDirector of Corp. CommunicationsDr. Li ZhangChief Production OfficerProf. Zhong Chen KouChief Scientist of ImmunologyDr. Xia Meng Ph.D.BS, Head of Early Diagnosis & InterventionMr. Michael HumphriesHead of Devel. & StrategyMore ExecutivesKey CompetitorsHarpoon TherapeuticsNASDAQ:HARPPrevail TherapeuticsNASDAQ:PRVLNeumora TherapeuticsNASDAQ:NMRAVir BiotechnologyNASDAQ:VIRGinkgo BioworksNYSE:DNAView All Competitors CBMG Stock Analysis - Frequently Asked Questions How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) posted its quarterly earnings results on Monday, November, 9th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter. What other stocks do shareholders of Cellular Biomedicine Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Amarin (AMRN), Anavex Life Sciences (AVXL), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), AT&T (T) and Iovance Biotherapeutics (IOVA). This page (NASDAQ:CBMG) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBill Clinton Backing Biden Replacement???The Freeport SocietyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaGet out of dollars—get into America’s new money insteadStansberry ResearchThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWrite this ticker symbol down…StocksToTradeGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellular Biomedicine Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.